Search

Context: When the epidemic first broke out, no specific treatment was available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The urgent need to end this unusual situation has resulted in many attempts to deal with SARS-CoV-2. In addition to several types of vaccinations that have been created, anti-SARS-CoV-2 monoclonal antibodies (mAbs) have added a new dimension to preventative and treatment efforts. This therapy also helps prevent severe symptoms for those at a high risk. Therefore, this is one of the most promising treatments for mild to moderate SARS-CoV-2 cases. However, the availability of anti-SARS-CoV-2 mAb therapy is limited and leads to two main challenges. The first is the privacy challenge of selecting eligible patients from the distribution hospital networking, which requires data sharing, and the second is the prioritization of all eligible patients amongst the distribution hospitals according to dose availability. To our knowledge, no research combined the federated fundamental approach with multicriteria decision-making methods for the treatment of SARS-COV-2, indicating a research gap. Objective: This paper presents a unique sequence processing methodology that distributes anti-SARS-CoV-2 mAbs to eligible high-risk patients with SARS-CoV-2 based on medical requirements by using a novel federated decision-making distributor. Method: This paper proposes a novel federated decision-making distributor (FDMD) of anti-SARS-CoV-2 mAbs for eligible high-risk patients. FDMD is implemented on augmented data of 49,152 cases of patients with SARS-CoV-2 with mild and moderate symptoms. For proof of concept, three hospitals with 16 patients each are enrolled. The proposed FDMD is constructed from the two sides of claim sequencing: central federated server (CFS) and local machine (LM). The CFS includes five sequential phases synchronised with the LMs, namely, the preliminary criteria setting phase that determines the high-risk criteria, calculates their weights using the newly formulated interval-valued spherical fuzzy and hesitant 2-tuple fuzzy-weighted zero-inconsistency (IVSH2-FWZIC), and allocates their values. The subsequent phases are federation, dose availability confirmation, global prioritization of eligible patients and alerting the hospitals with the patients most eligible for receiving the anti-SARS-CoV-2 mAbs according to dose availability. The LM independently performs all local prioritization processes without sharing patients' data using the provided criteria settings and federated parameters from the CFS via the proposed Federated TOPSIS (F-TOPSIS). The sequential processing steps are coherently performed at both sides. Results and Discussion: (1) The proposed FDMD efficiently and independently identifies the high-risk patients most eligible for receiving anti-SARS-CoV-2 mAbs at each local distribution hospital. The final decision at the CFS relies on the indexed patients' score and dose availability without sharing the patients' data. (2) The IVSH2-FWZIC effectively weighs the high-risk criteria of patients with SARS-CoV-2. (3) The local and global prioritization ranks of the F-TOPSIS for eligible patients are subjected to a systematic ranking validated by high correlation results across nine scenarios by altering the weights of the criteria. (4) A comparative analysis of the experimental results with a prior study confirms the effectiveness of the proposed FDMD. Conclusion: The proposed FDMD has the benefits of centrally distributing anti-SARS-CoV-2 mAbs to high-risk patients prioritized based on their eligibility and dose availability, and simultaneously protecting their privacy and offering an effective cure to prevent progression to severe SARS-CoV-2 hospitalization or death. [ABSTRACT FROM AUTHOR]

In the fuzzy multicriteria decision-making approach, a committee of decision-makers is usually involved in the assessment of the suitability of different alternatives based on the evaluation criteria by using linguistic terms and their equivalent fuzzy numbers. In this context, researchers have developed the Pythagorean fuzzy set (PFS) to overcome the limitation of intuitionistic fuzzy set in the description of decision-maker information such as imposing restrictions on the representation of membership and nonmembership grades. On the one hand, PFS still does not have sufficient ability and flexibility to deal with such issues. On the other hand, multipolar technology is used to operate large-scale systems in real-life situations, especially in dealing with dissatisfaction and indeterminacy grades for the alternatives of the reference set. Thus, m-polar fuzzy set is utilized and applied with other fuzzy sets because of its remarkable ability as a tool for depicting fuzziness and uncertainty under multipolar information in many circumstances. With the practical features of m-polar fuzzy set in combination with PFS, this paper employs it to extend two considerable MCDM methods, namely, fuzzy decision by opinion score method and fuzzy-weighted zero inconsistency. Such extensions, called Pythagorean m-polar fuzzy-weighted zero-inconsistency (Pm-PFWZIC) method and Pythagorean m-polar fuzzy decision by opinion score method (Pm-PFDOSM), are formulated to weight the evaluation criteria followed by alternative ranking progressively. The research methodology is presented as follows. Firstly, the mechanisms of Pm-PFWZIC and Pm-PFDOSM are formulated and integrated into the development phase. Secondly, the description of the real-world case study of the evaluation and benchmarking of the sign language recognition systems is adapted and presented. The result of Pm-PFWZIC shows that the criterion of 'finger movements' has the highest weight amongst the rest of the criteria, whereas 'misclassification error' has the lowest weight. In the ranking results, a variation of ranking is scored by each expert, and group decision-making is applied to solve the individual ranking variety. The robustness of the formulated methods is evaluated using systematic ranking, sensitivity analysis and comparison analysis. [ABSTRACT FROM AUTHOR]